Methods and compositions for the inhibition of fructokinase

Patent metadata

Field	Value
Publication number	US-9387245-B2
Application number	US-201113814568-A
Country	US
Kind code	B2
Filing date	Aug 8, 2011
Priority date	Aug 6, 2010
Publication date	Jul 12, 2016
Grant date	Jul 12, 2016

Abstract

The invention relates to the use of isoform-specific fructokinase (ketohexokinase) (KHK) inhibitors alone or in combination with various agents to both prevent and treat a wide variety of diseases including, but not limited to, sugar craving, obesity, features of metabolic syndrome (including insulin resistance, hypertriglyceridemia, hypertension, and fatty liver), polyuria, proximal tubular injury, and diabetic kidney disease.

First claim

We claim:

1. A method for diminishing, inhibiting or eliminating addiction-related behavior of a human, said method comprising
identifying said human as having a fructose and/or sucrose addiction; and administering to said human an effective amount of a composition comprising a ketohexokinase C (KHK-C) inhibitor to diminish said fructose and/or sucrose addition.

2. A method for treating or protecting against acute kidney injury (AKI) in a subject, the method comprising administering a composition comprising a KHK-C inhibitor; wherein said AKI that is treated or protected against is AKI associated with administration of a contrast agent; AKI associated with cardiovascular surgery; or AKI associated with sepsis.

3. The method of claim 2 , wherein the KHK-C inhibitor inhibits KHK-C, but does not inhibit KHK-A.

4. The method of claim 2 , wherein the KHK-C inhibitor comprises at least one member of the group consisting of a ribozyme, an interfering molecule, a peptide, a small molecule, or an antibody targeted to KHK-C.

5. The method of claim 4 , wherein the KHK-C inhibitor comprises an interfering molecule, and wherein the interfering molecule comprises a member from the group consisting of a phosphorothioate morpholino oligomer (PMO), miRNA, sRNA, methylated sRNA, shRNA, antisense RNA, a dicer-substrate 27-mer duplex, and any combination thereof.

6. The method of claim 2 , wherein the administering is done to treat or prevent acute tubular injury.

7. The method of claim 2 , further comprising administering to the subject a conjunctive agent, wherein the conjunctive agent comprises a compound selected from the group consisting of angiotensin-converting enzyme (ACE) inhibitors, aldosterone antagonists, amphetamines, amphetamine-like agents, Angiotensin II receptor antagonists, anti-oxidants, aldose reductase inhibitors, biguanides, sorbitol dehydrogenase inhibitors, thiazolidinediones (glitazones), thiazide and thiazide-like diuretics, triglyceride synthesis inhibitors, xanthine oxidase inhibitors, and combinations thereof.

8. A method of treating diabetic nephropathy in a subject, said method comprising administering a KHK-C inhibitor to the subject, wherein the KHK-C inhibitor does not inhibit KHK-A.

Assignees

• Johnson Richard J
• Lanaspa-Garcia Miguel A
• Ishimoto Takuji
• Univ Colorado Regents

Inventors

• Johnson Richard J
• Lanaspa-Garcia Miguel A
• Ishimoto Takuji

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P25/30

  for treating abuse or dependence · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title